Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

This study is testing whether adding orelabrutinib (a targeted therapy) to a standard chemotherapy regimen (called Pola-R-CHP) helps improve outcomes for patients with newly diagnosed non-GCB diffuse large B-cell lymphoma — a specific subtype of aggressive blood cancer. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with diffuse large B-cell lymphoma (DLBCL), non-GCB subtype, confirmed by biopsy - You have not yet received any treatment for this cancer - You have at least one measurable tumor - Your overall health is adequate (ECOG 0–2) - Your life expectancy is at least 6 months **You may NOT be eligible if...** - Your lymphoma has spread to the brain or spinal fluid - Your DLBCL was transformed from another type of lymphoma - You have primary mediastinal large B-cell lymphoma or Burkitt lymphoma - Your blood counts (white blood cells, platelets) are too low at screening - Your liver enzymes (ALT or AST) are significantly elevated Talk to your doctor to see if this trial is right for you.